People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination

Front Immunol. 2024 Jan 17:14:1235210. doi: 10.3389/fimmu.2023.1235210. eCollection 2023.

Abstract

People who use drugs (PWUD) are at a high risk of contracting and developing severe coronavirus disease 2019 (COVID-19) and other infectious diseases due to their lifestyle, comorbidities, and the detrimental effects of opioids on cellular immunity. However, there is limited research on vaccine responses in PWUD, particularly regarding the role that T cells play in the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we show that before vaccination, PWUD did not exhibit an increased frequency of preexisting cross-reactive T cells to SARS-CoV-2 and that, despite the inhibitory effects that opioids have on T-cell immunity, standard vaccination can elicit robust polyfunctional CD4+ and CD8+ T-cell responses that were similar to those found in controls. Our findings indicate that vaccination stimulates an effective immune response in PWUD and highlight targeted vaccination as an essential public health instrument for the control of COVID-19 and other infectious diseases in this group of high-risk patients.

Keywords: SARS-CoV-2 vaccination; T cell functionality; T cell responses; T cell subsets; antiviral immunity; opioids and immune responses; people who use drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid
  • COVID-19*
  • Communicable Diseases*
  • Humans
  • RNA, Messenger
  • SARS-CoV-2
  • Vaccination

Substances

  • Analgesics, Opioid
  • RNA, Messenger

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by The Coalition for Epidemic Preparedness Innovations/NEC Oncoimmunity AS (2021-N-1), The Research Council of Norway (316277), The University of Oslo (KGJ-19), and The South-Eastern Norway Regional Health Authority/ Oslo University Hospital (HSØ-29286).